What is the recommended assessment and treatment plan for eczema?

Eczema Assessment and Treatment Plan

For eczema management, establish diagnosis clinically based on pruritic inflammatory skin lesions with typical distribution, then implement a stepwise treatment approach starting with daily moisturizers as foundational therapy, adding topical corticosteroids as first-line anti-inflammatory treatment, and escalating to topical calcineurin inhibitors for sensitive areas or systemic therapies for moderate-to-severe disease that fails topical management. 1

Clinical Assessment

Diagnostic Criteria

Diagnose atopic dermatitis clinically without requiring laboratory testing 2. Look for these specific features:

Essential findings:

• Pruritus (hallmark symptom - if there's no itch, reconsider the diagnosis)
• Chronic or relapsing inflammatory skin lesions
• Typical morphology: erythema, edema, xerosis, erosions/excoriations, oozing/crusting, lichenification (varies by chronicity)
• Age-appropriate distribution patterns

Supporting features:

• Personal or family history of atopic conditions (allergic rhinitis, asthma)
• Elevated IgE levels (supportive but not required)
• Onset typically between 3-6 months of age (60% by first year, 90% by age 5) 2

Critical caveat: Rule out allergic contact dermatitis or irritant contact dermatitis through comprehensive history and physical examination. Consider patch testing or biopsy if presentation is atypical 1.

Treatment Algorithm

Step 1: Foundation - Moisturizers (ALL patients)

Apply moisturizers liberally and frequently to all patients regardless of severity 1. This is non-negotiable baseline therapy.

• Reduces AD severity, signs, symptoms, and inflammation
• Increases time between flares
• Targets xerosis by minimizing transepidermal water loss
• Strong recommendation based on moderate certainty evidence 1
• No specific moisturizer formulation can be recommended over another based on current evidence 1

Step 2: Topical Anti-Inflammatory Therapy

For active inflammation, use topical corticosteroids (TCS) as first-line pharmacologic treatment 1, 3:

• Apply once daily, not twice daily - evidence shows no additional benefit from twice-daily application 4
• Select potency based on severity and body location
• Use for flare management and consider proactive maintenance therapy 3

For sensitive skin areas (face, eyelids, intertriginous areas) or long-term control:

• Use topical calcineurin inhibitors (tacrolimus, pimecrolimus) preferentially 3, 4
• Particularly valuable for facial and genital areas where TCS risks are higher

Alternative topical options when available:

• Topical JAK inhibitors 1, 5
• PDE-4 inhibitors (crisaborole) 1, 6
• Topical phosphodiesterase inhibitors 3

Step 3: Adjunctive Measures

Wet wrap therapy: Conditional recommendation for use as adjunctive treatment 1, 6

Bathing practices: Recommended as part of comprehensive management 1

Dilute bleach baths: May be considered based on recent guideline recommendations 6

Step 4: Escalation for Moderate-to-Severe Disease

When topical therapies fail to control disease, escalate systematically 5:

Phototherapy:

• UVB 311 nm (narrowband UVB) preferred
• UVA1 as alternative 3

Systemic therapies for refractory disease:

• Biologics: Dupilumab, nemolizumab, tralokinumab 5, 6
• JAK inhibitors: Baricitinib, upadacitinib, abrocitinib 5, 6
• Traditional immunosuppressants: Cyclosporine, methotrexate, azathioprine, mycophenolate 6, 5

What NOT to Do

Avoid these interventions - they lack supporting evidence:

• Oral antihistamines for eczema treatment (not recommended despite common use) 4, 1
• Topical or oral antimicrobials for routine use (recommendation against) 1, 4
• Topical antiseptics routinely 1
• Probiotics for treating established eczema 4
• Silk clothing 4
• Ion-exchange water softeners 4
• Emollient bath additives (not shown to benefit) 4
• Dietary elimination without clear indication 6
• Systemic corticosteroids for long-term management (use only for acute severe flares if at all) 6

Maintenance Strategy

Implement "get control then keep control" regimen 4:

• Aggressively treat flares to achieve complete control
• Transition to proactive maintenance therapy with anti-inflammatory agents applied to previously affected areas
• Continue daily moisturization indefinitely
• This approach prevents flares more effectively than reactive treatment alone

Common Pitfalls

• Under-treatment: Most common error - be more aggressive with topical therapies initially 4
• Corticosteroid phobia: Address patient concerns about TCS safety while emphasizing risks of under-treatment
• Twice-daily TCS application: Wastes medication and increases cost without benefit 4
• Delaying systemic therapy: Don't let patients suffer with severe disease - systemic options are now safer and more effective 5
• Using antihistamines expecting disease modification: They don't treat eczema, only potentially help sleep if pruritus is severe